135 related articles for article (PubMed ID: 3521926)
1. Pharmacokinetics and plasma protein binding of two platinum cytostatics CHIP and CBDCA in rats.
Láznícková A; Láznícek M; Kvĕtina J; Drobník J
Cancer Chemother Pharmacol; 1986; 17(2):133-6. PubMed ID: 3521926
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function.
Harland SJ; Newell DR; Siddik ZH; Chadwick R; Calvert AH; Harrap KR
Cancer Res; 1984 Apr; 44(4):1693-7. PubMed ID: 6367971
[TBL] [Abstract][Full Text] [Related]
3. The comparative pharmacokinetics of carboplatin and cisplatin in mice and rats.
Siddik ZH; Newell DR; Boxall FE; Harrap KR
Biochem Pharmacol; 1987 Jun; 36(12):1925-32. PubMed ID: 3297068
[TBL] [Abstract][Full Text] [Related]
4. Blood clearance of radioactively labelled cis-diammine 1,1-cyclobutane dicarboxylate platinum (II) (CBDCA) in cancer patients.
Sharma H; Thatcher N; Baer J; Zaki A; Smith A; McAucliffe CA; Crowther D; Owens S; Fox BW
Cancer Chemother Pharmacol; 1983; 11(1):5-7. PubMed ID: 6349844
[TBL] [Abstract][Full Text] [Related]
5. Comparative pharmacokinetics of four platinum cytostatics in rats.
Láznícková A; Filipová M; Láznícek M; Drobník J; Svoboda D; Kvĕtina J
Neoplasma; 1987; 34(2):173-81. PubMed ID: 3600883
[TBL] [Abstract][Full Text] [Related]
6. In vivo distribution studies of radioactively labelled platinum complexes; cis-dichlorodiammine platinum(II), cis-trans-dichlorodihydroxy-bis-(isopropylamine) platinum(IV), cis-dichloro-bis-cyclopropylamine platinum(II), and cis-diammine 1,1-cyclobutanedicarboxylate platinum(II) in patients with malignant disease, using a gamma camera.
Owens SE; Thatcher N; Sharma H; Adam N; Harrison R; Smith A; Zaki A; Baer JC; McAuliffe CA; Crowther D
Cancer Chemother Pharmacol; 1985; 14(3):253-7. PubMed ID: 3888431
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the reactions of platinum antitumor agents with biologic and nonbiologic sulfur-containing nucleophiles.
Dedon PC; Borch RF
Biochem Pharmacol; 1987 Jun; 36(12):1955-64. PubMed ID: 2954556
[TBL] [Abstract][Full Text] [Related]
8. Effect of oxoplatinum and CBDCA on renal functions in rats.
Láznícková A; Semecký V; Láznícek M; Zubr V; Koksál J; Kvĕtina J
Neoplasma; 1989; 36(2):161-9. PubMed ID: 2654665
[TBL] [Abstract][Full Text] [Related]
9. Studies on the pharmacokinetics and metabolism of cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum(IV) in the dog.
Pendyala L; Cowens JW; Creaven PJ
Cancer Treat Rep; 1982 Mar; 66(3):509-16. PubMed ID: 7060038
[TBL] [Abstract][Full Text] [Related]
10. Comparison of intestinal toxic effects of platinum complexes: cisplatin (CDDP), carboplatin (CBDCA), and iproplatin (CHIP).
Kralovánszky J; Prajda N; Kerpel-Fronius S; Gál F; Kiss F
Cancer Chemother Pharmacol; 1988; 21(1):40-4. PubMed ID: 3277733
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum IV (CHIP) in patients with advanced cancer.
Pendyala L; Greco W; Cowens JW; Madajewicz S; Creaven PJ
Cancer Chemother Pharmacol; 1983; 11(1):23-8. PubMed ID: 6883623
[TBL] [Abstract][Full Text] [Related]
12. The influence of platinum drugs on the radiation response of rat kidneys.
van Rongen E; Kuijpers WC; Baten-Wittwer A
Radiother Oncol; 1994 May; 31(2):138-50. PubMed ID: 8066193
[TBL] [Abstract][Full Text] [Related]
13. Preclinical studies on toxicity, antitumour activity and pharmacokinetics of cisplatin and three recently developed derivatives.
Lelieveld P; Van der Vijgh WJ; Veldhuizen RW; Van Velzen D; Van Putten LM; Atassi G; Danguy A
Eur J Cancer Clin Oncol; 1984 Aug; 20(8):1087-104. PubMed ID: 6381064
[TBL] [Abstract][Full Text] [Related]
14. [Study on nephrotoxicity in rats receiving cis-diammine-1,1-cyclobutane dicarboxylate platinum II--special reference to morphological changes].
Kimura S; Nakajima Y; Hasegawa S; Tazaki H
Nihon Hinyokika Gakkai Zasshi; 1989 Apr; 80(4):517-25. PubMed ID: 2664296
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function.
Egorin MJ; Van Echo DA; Tipping SJ; Olman EA; Whitacre MY; Thompson BW; Aisner J
Cancer Res; 1984 Nov; 44(11):5432-8. PubMed ID: 6386150
[TBL] [Abstract][Full Text] [Related]
16. Vestibular morphological analysis of the effects of cisplatin vs. platinum analogs, CBDCA (JM-8) and CHIP (JM-9).
Schweitzer VG; Rarey KE; Dolan DF; Abrams GE; Sheridan C
Laryngoscope; 1986 Sep; 96(9 Pt 1):959-74. PubMed ID: 3528727
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum IV (iproplatinum, CHIP) in patients with normal and impaired renal function and following intraperitoneal administration.
Kerr DJ; Harding M; Farmer JG; Amarin J; Blackie RG; Harland SJ; Kaye SB
Med Oncol Tumor Pharmacother; 1988; 5(3):153-8. PubMed ID: 3412038
[TBL] [Abstract][Full Text] [Related]
18. In vivo and in vitro effectivity of some platinum complexes.
Balázová E; Hrubisko M; Ujházy V
Neoplasma; 1984; 31(6):641-7. PubMed ID: 6395026
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.
Knox RJ; Friedlos F; Lydall DA; Roberts JJ
Cancer Res; 1986 Apr; 46(4 Pt 2):1972-9. PubMed ID: 3512077
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum II (CBDCA) in humans].
Zucca E; Cattaneo MT; Cavalli F; Guaitani A; Filipazzi V; Bartosek I
G Ital Chemioter; 1985; 32(1):25-8. PubMed ID: 3913618
[No Abstract] [Full Text] [Related]
[Next] [New Search]
